The Fifth INTEnsive pReventing Secondary Injury in Acute Cerebral Haemorrhage Trial Within ACT-GLOBAL

Inclusion Criteria: 1. Age between 18 and 80 years old 2. Diagnosis of presumed spontaneous supratentorial intracerebral haemorrhage, confirmed by brain imaging 3. Presentation to hospital within 24 hours of symptom onset (or last seen well) 4. Hematoma volume ≥10 mL or any volume post-surgery 5. NIHSS score \>8 6. GCS ≥8 7. Provide written informed consent by patient (or approved surrogate) Exclusion Criteria: 1. Secondary cause of haemorrhage (e.g., structural abnormality such as arteriovenous malformation, cerebral aneurysm, tumour, trauma), or haemorrhagic transformation of acute ischaemic stroke 2. Isolate intraventricular haemorrhage 3. Chronic Kidney Disease 4. Very high likelihood of death within 7 days or poor adherence to study treatment or follow-up 5. Severe comorbid disease that will interfere with outcome assessments (e.g., cancer, chronic airflow disease, heart failure, significant disability) 6. Women who are pregnant or lactating Exclusion Criteria related to use of deferoxamine: 7. Previous chelation therapy or known hypersensitivity to deferoxamine products; 8. Severe iron deficiency anaemia (haemoglobin \<7 g/dL or requiring regular blood transfusions); 9. Taking iron supplements containing \>325 mg of ferrous iron; 10. Serum creatinine \>2 mg/dL; 11. Patients with known heart failure taking \>500 mg of vitamin C Exclusion criteria related to the use of colchicine: 12. Allergic to colchicine 13. Myelodysplastic hypoplasia, or liver or severe renal failure 14. Use of medication which may interact with colchicine (e.g., strong CYPsA4 inhibitors such as ketoconazole, strong P-glycoprotein inhibitors such as fluconazole)